- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Fall 2015
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Aggrenox | Boehringer Ingelheim | Aspirin / Extended-Release Dipyridamole Capsules | Teva | reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis | 7/1/2015 |
Axert | Janssen | Almotriptan Malate Tablets | Teva | acute treatment of migraine attacks in adults with a history of migraine with or without aura; acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more | 7/8/2015 |
Targretin | Valeant | Bexarotene | Mylan | treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy | 7/9/2015 |
Namenda | Forest Labs | Memantine Hydrochloride Tablets | Amneal Pharms | treatment of moderate to severe dementia of the Alzheimer's type | 7/11/2015 |
Namenda | Merz Pharma | Memantine Hydrochloride Tablets | Dr. Reddy's Labs | treatment of moderate to severe dementia of the Alzheimer's type | 7/12/2015 |
Tobi | Novartis | Tobramycin Inhalation Solution | Amneal Pharms | for the management of cystic fibrosis patients with Pseudomonas aeruginosa | 7/13/2015 |
Namenda | Forest Labs | Memantine Hydrochloride Tablets | Mylan | treatment of moderate to severe dementia of the Alzheimer's type | 7/14/2015 |
Angiomax | The Medicines Company | Bivalirudin for Injection | Hospira | indicated as an anticoagulant | 7/16/2015 |
Pulmicort | AstraZeneca | Budesonide Inhalation Suspension | Sandoz | indicated for maintenance treatment of asthma and as a prophylactic therapy in children 12 months to 8 years of age | 7/28/2015 |
Megace ES | E. R. Squibb & Sons | Megestrol Acetate, USP, Oral Suspension | Par Pharm | indicated for the treatment of anorexia, cachexia, or an unexplained significant weigh loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) | 7/29/2015 |
Sodium Edecrin | Alton Pharma | Ethrynate Sodium for Injection USP | Par Pharm | treatment of edema | 8/4/2015 |
Nexium | AstraZeneca | Esomeprazole Magnesium Delayed-Release Capsules | Mylan | treatment of gastroesophageal reflux disease (GERD) in adults and children ages 1 and older | 8/5/2015 |
Lidoderm | Endo Pharm | Lidocaine Patch 5% | Mylan | indicated for relief of pain associated with post-herpetic neuralgia | 8/10/2015 |
Mirapex ER | Boehringer Ingelheim | Pramipexole Dihydrochloride ER Tablets | Dr. Reddy's Labs | treatment for Parkinson's disease | 8/11/2015 |
Xenazine | Valeant | Tetrabenazine | Sun Pharm |
treatment
of chorea associated with Huntington’s disease.
|
8/17/2015 |
Abilify | Bristol-Myers Squibb | Aripiprazole Oral Solution | Amneal Pharms | add-on treatment to an antidepressant for adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy. Treatment of manic or mixed episodes associated with Bipolar I Disorder I adults and in pediatric patients 10 to 17 years of age. Treatment of Schizophrenia in adults and in adolescents 13 to 17 years of age. Treatment of irritability associated with Autistic Disorder in pediatric patients 6 to 17 years of age. Treatment of Tourette's Disorder in pediatric patients 6 to 18 years of age. | 8/18/2015 |
Abilify | Bristol-Myers Squibb | Aripiprazole Oral Solution | Silarx Pharms | add-on treatment to an antidepressant for adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy. Treatment of manic or mixed episodes associated with Bipolar I Disorder I adults and in pediatric patients 10 to 17 years of age. Treatment of Schizophrenia in adults and in adolescents 13 to 17 years of age. Treatment of irritability associated with Autistic Disorder in pediatric patients 6 to 17 years of age. Treatment of Tourette's Disorder in pediatric patients 6 to 18 years of age. | 8/18/2015 |
Yaz | Bayer HealthCare | Drospirenone / Ethinyl Estradiol Tablets | Glenmark Pharms | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 8/19/2015 |
Zosyn | Pfizer | Piperacillin / Tazobactam for Injection | Mylan | indicated for treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria | 8/25/2015 |
Dibenzyline | WellSpring Pharms | Phenoxybenzamine Hydrochloride Capsules | Roxane Labs | treating high blood pressure and sweating caused by a certain kind of tumor (pheochromocytoma) | 8/25/2015 |
Exelon | Novartis | Rivastigmine Transdermal System | Alvogen | treatment of mild, moderate, and severe dementia of the Alzheimer’s type, and mild to moderate dementia associated with Parkinson’s disease. | 8/31/2015 |
Exelon | Novartis | Rivastigmine Transdermal System | Sandoz | treatment of mild, moderate, and severe dementia of the Alzheimer’s type, and mild to moderate dementia associated with Parkinson’s disease. | 8/31/2015 |
Cymbalta DR | Eli Lilly and Co. | Duloxetine DR Capsules | Lupin | Major Depressive Disorder; Generalized Anxiety Disorder; Diabetic Peripheral Neuropathic Pain; Chronic Musculoskeletal Pain | 9/3/2015 |
Vfend | PF Prism | Voriconazole Tablets | Glenmark Pharms | treating certain fungal infections | 9/4/2015 |
Yasmin | Bayer | Drospirenone / Ethinyl Estradiol Tablets | Mylan | indicated for use by women to prevent pregnancy | 9/8/2015 |
Unasyn | Pfizer | Ampicillin / Sulbactam for Injection | Mylan | indicated for the treatment of infections due to susceptible strains of designated microorganisms in skin and skin structure infections, intra-abdominal infections and gynecological infections | 9/14/2015 |
Lescol XL | Novartis | Fluvastatin Sodium ER Tablets | Mylan | indicated to reduce elevated total cholesterol, LDL-C, Apo B, and triglyceride and increase HDL-C in adults with primary hypercholesterolemia and mixed dyslipidemia | 9/18/2015 |
BenzaClin | Valeant | Phosphate 1% / Benzoyl Peroxide 5% | Perrigo | indicated for the topical treatment of acne vulgaris | 9/22/2015 |
Invega | Janssen | Paliperidone ER Tablets | Allergan | treatment of schizophrenia in adults and adolescents (12-17 years of age) | 9/25/2015 |
Invega | Janssen | Paliperidone ER Tablets | Patriot Pharm | treatment of schizophrenia in adults and adolescents (12-17 years of age) | 9/25/2015 |
Nexium | AstraZeneca | Esomeprazole Magnesium DR Capsules | Dr. Reddy's Labs | treatment of gastroesophageal reflux disease (GERD) in adults and children ages 1 and older | 9/28/2015 |
Invega | Janssen | Paliperidone ER Tablets | Mylan | treatment of schizophrenia in adults and adolescents (12-17 years of age) in addition to schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults | 9/28/2015 |
Orap | Teva | Pimozide | Par Pharm | antipsychotic indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment | 9/30/2015 |
GENERICally Speaking Fall 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.